Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6091 to 6105 of 8216 results

  1. Chronic obstructive pulmonary disease: olodaterol (ESNM54)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    3 February 2015

  2. Asthma: tiotropium (Spiriva Respimat) (ESNM55)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    3 March 2015

  3. Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

    This evidence summary has been updated and replaced by NICE guideline NG81.

    Evidence summary
    Published
    17 March 2015

  4. Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    28 April 2015

  5. Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

    This evidence summary has been updated and replaced by NICE guideline NG130.

    Evidence summary
    Published
    16 June 2015

  6. Alcohol dependence: nalmefene (ESNM29)

    This evidence summary has been replaced by NICE technology appraisal guidance 325.

    Evidence summary
    Published
    17 December 2013

  7. Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    12 October 2012

  8. Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Evidence summary
    Published
    13 January 2014

  9. Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA‑SC) (ESNM31)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Evidence summary
    Published
    28 January 2014

  10. Relapsed and refractory multiple myeloma: pomalidomide (ESNM32)

    This evidence summary has been replaced by NICE technology appraisal guidance 338 [Replaced by NICE technology appraisal guidance 427]

    Evidence summary
    Published
    4 February 2014

  11. Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    11 February 2014

  12. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    3 March 2014

  13. Type 2 diabetes: empagliflozin (ESNM35)

    This evidence summary has been replaced by NICE technology appraisal guidance 336.

    Evidence summary
    Published
    11 March 2014

  14. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Evidence summary
    Published
    18 March 2014

  15. Induction of labour: misoprostol vaginal delivery system (ESNM38)

    We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.

    Evidence summary
    Published
    25 March 2014